HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis

Table 4

Meta-analysis on HBV reactivation among patients treated with etanercept.

(a)  

First author, year	Number of patients	HBV reactivation (𝑛)	HBV reactivation (%)	CI 95%	Weight (%)
All  patients
Caporali et al., 2010 [11]	23	0	0.0	0.0–14.3	12.4
Cassano et al., 2011 [12]	44	0	0.0	0.0–8.0	16.9
Lan et al., 2011 [15]	40	3	7.5	2.6–19.9	16.2
Mori, 2011 [16]	19	0	0.0	0.0–16.8	11.2
Ryu et al., 2012 [17]	38	2	5.3	1.5–17.3	15.9
Tamori et al., 2011 [18]	20	0	0.0	0.0–16.1	11.5
Urata et al., 2011 [19]	38	5	13.2	5.7–27.3	15.9
Pooled estimate			3.9	1.1–8.4	100.0

Heterogeneity chi-squared = 12.26 (d.f. = 6) 𝑃 = 0.056.
𝐼-squared (variation in ES attributable to heterogeneity) = 51.1%.

(b)  

First author, year	Number of patients	HBV reactivation (𝑛)	HBV reactivation (%)	CI 95%	Weight (%)
Patients  with  occult  HBV  infection
Caporali et al., 2010 [11]	23	0	0.0	0.0–14.3	15.3
Cassano et al., 2011 [12]	44	0	0.0	0.0–8.0	20.6
Lan et al., 2011 [15]	31	1	3.2	0.6–16.2	17.7
Mori, 2011 [16]	18	0	0.0	0.0–17.6	13.3
Tamori et al., 2011 [18]	19	0	0.0	0.0–16.8	13.7
Urata et al., 2011 [19]	38	5	13.2	5.7–27.3	19.4
Pooled estimate			3.0	0.5–7.6	100.0

Heterogeneity chi-squared = 9.93 (d.f. = 5) 𝑃 = 0.077.
𝐼-squared (variation in ES attributable to heterogeneity) = 49.6%.